Short Interest in I-Mab Sponsored ADR (NASDAQ:IMAB) Increases By 38.8%

I-Mab Sponsored ADR (NASDAQ:IMAB - Get Free Report) saw a significant growth in short interest in October. As of October 15th, there was short interest totaling 3,650,000 shares, a growth of 38.8% from the September 30th total of 2,630,000 shares. Approximately 5.7% of the company's stock are short sold. Based on an average trading volume of 2,660,000 shares, the short-interest ratio is currently 1.4 days. Based on an average trading volume of 2,660,000 shares, the short-interest ratio is currently 1.4 days. Approximately 5.7% of the company's stock are short sold.I-Mab Trading Up 2.5%NASDAQ IMAB traded up $0.12 during trading hours on Monday, reaching $4.76. The company's stock had a trading volume of 1,512,693 shares, compared to its average volume of 2,165,293. The business has a 50-day simple moving average of $4.46 and a 200 day simple moving average of $2.93. I-Mab has a 52 week low of $0.60 and a 52 week high of $6.79. The stock has a market cap of $388.29 million, a PE ratio of -13.21 and a beta of 1.45. I-Mab (NASDAQ:IMAB - Get Free Report) last released its quarterly earnings results on Wednesday, August 20th. The company reported ($0.07) earnings per share for the quarter, beating analysts' consensus estimates of ($0.10) by $0.03. As a group, equities analysts predict that I-Mab will post -0.56 EPS for the current year. Institutional Inflows and OutflowsHedge funds have recently made changes to their positions in the stock. Ground Swell Capital LLC acquired a new position in shares of I-Mab during the first quarter valued at approximately $53,000. Stonepine Capital Management LLC acquired a new position in shares of I-Mab during the first quarter valued at approximately $398,000. Geode Capital Management LLC grew its position in I-Mab by 147.6% in the second quarter. Geode Capital Management LLC now owns 54,562 shares of the company's stock worth $132,000 after buying an additional 32,525 shares during the last quarter. Finally, SG Americas Securities LLC grew its position in I-Mab by 6.6% in the second quarter. SG Americas Securities LLC now owns 876,353 shares of the company's stock worth $2,121,000 after buying an additional 54,312 shares during the last quarter. Institutional investors and hedge funds own 38.38% of the company's stock. Analyst Ratings ChangesIMAB has been the subject of several recent analyst reports. Needham & Company LLC restated a "buy" rating and set a $6.00 target price on shares of I-Mab in a research note on Friday, October 24th. Loop Capital set a $8.00 target price on I-Mab in a research note on Thursday, August 28th. Citigroup restated a "buy" rating on shares of I-Mab in a research note on Monday, October 27th. Leerink Partners initiated coverage on shares of I-Mab in a research report on Friday, October 3rd. They set an "outperform" rating and a $9.00 price target on the stock. Finally, HC Wainwright reaffirmed a "buy" rating and set a $7.00 price target on shares of I-Mab in a research report on Monday, October 27th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $7.67.Check Out Our Latest Analysis on I-MabAbout I-Mab (Get Free Report)I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases primarily in the United States. It is developing Uliledlimab, a CD73 neutralizing antibody, which is in Phase 2 clinical trial for the treatment of solid tumors; Givastomig, a bi-specific antibody that is in Phase 1 clinical trial for the treatment of gastric and other cancers; and Ragistomig, a programmed cell death ligand-based tumor-dependent T cell engager, which is in Phase 1 clinical trial for the treatment of for solid tumors.Recommended StoriesFive stocks we like better than I-MabBuy P&G Now, Before It Sets A New All-Time HighSemiconductor Supercycle: Why Onsemi Stock Could Double as AI and EV Growth AccelerateHow to trade using analyst ratingsThe Best Local Butchers for Thanksgiving [2025 Survey]Ride Out The Recession With These Dividend Kings $134M in Insider Moves: What It Might Mean for KMI, ISRG and QSThis instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in I-Mab Right Now?Before you consider I-Mab, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and I-Mab wasn't on the list.While I-Mab currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here